Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$7.87
-$0.24(-2.76%)
At close: 4:00 PM EDT
$7.87
-$0.24(-2.76%)
Day’s Range― - ―
52-Week Range$3.02 - $49.60
Previous Close$8.46
Volume52.72K
Average Volume (3M)83.58K
Market Cap
$17.59M
Enterprise Value$11.29
Total Cash (Recent Filing)$7.69M
Total Debt (Recent Filing)$693.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Apr 21, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1600.00
Shares Outstanding1,946,982
10 Day Avg. Volume80,354
30 Day Avg. Volume83,578
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.50Price Target Upside224.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-10.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces interest and refinancing pressure while preserving flexibility to direct available capital toward clinical development. Although the capital base is weakening, the lightly levered balance sheet limits fixed financial obligations during the company’s development stage.
Focused Therapeutic StrategyA concentrated focus on autoimmune and inflammatory diseases gives Akari a defined development strategy rather than a broad, diffuse research agenda. Specialization in complement and immune pathways may help align research resources and clinical programs around related therapeutic opportunities.
Financing AccessCompleted equity funding and approved issuance capacity provide a mechanism to finance ongoing development activities over the coming periods. This improves operational continuity relative to an immediate funding shortfall, even though future issuances may dilute existing holders.
Bears Say
No RevenueThe absence of revenue means Akari has not yet demonstrated commercial demand or an internally generated funding stream. Continued reliance on development milestones and external capital leaves financial performance highly dependent on future product progress rather than an established operating business.
Widening LossesRapidly widening losses are reducing the company’s equity base and indicate that operating costs are increasing faster than any progress toward revenue generation. Persistent deterioration can constrain strategic flexibility and raise the amount of capital required to sustain clinical development.
Persistent Cash Burn And DilutionNegative operating and free cash flow indicate that Akari cannot currently fund its activities internally. The resulting dependence on equity financing, warrants and further authorized issuance creates ongoing dilution risk and may make future capital needs a recurring constraint on shareholder value.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $49.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $17.59M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Apr 21, 2027 which is in 208 days.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $1.04.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 1,946,982 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 7.714%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Stock 12 Month Forecast
Average Price Target
$25.50
▲(224.02% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
7.32% Other Institutional Investors
67.02% Public Companies and
Individual Investors